BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society meeting...
5 KB (257 words) - 14:14, 4 February 2023
Beclabuvir (BMS-791325) – phase III BMS-906024 – phase I BMS-955176 – phase II Brivanib alaninate (BMS-582664) – development terminated Elotuzumab (BMS-901608)...
97 KB (7,693 words) - 19:20, 11 November 2024